Stock Watch: Unconventional Biosimilar Wisdom
Don't Assume The US Is Easier For Innovator Product Defenders
Executive Summary
Conventional wisdom from the first biosimilar launches was that the European market that was far tougher on innovator products than was the US. More recent data suggest that things may play out differently in the long run.